Hims & Hers Health, Inc. (HIMS)
Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook
Two healthcare names are drawing fresh analyst attention this week as Wall Street recalibrates around a landmark GLP-1 truce and a fertility benefits company navigating a murky 2026 outlook.
Hims and Hers Expands Consumer-Focused Digital Health Platform
HIMS expands its digital care platform with new specialties, lab testing and global moves as it scales personalized telehealth services.
Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is HIMS stock the best buy in March 2026?
Shares of Hims & Hers Health (NYSE: HIMS) have staged a sharp rebound after drugmaker Novo Nordisk (NYSE: NVO) dropped its lawsuit against the company, removing what many investors considered the biggest risk.
Hims & Hers Health: The Juice Is Worth The Squeeze
Hims & Hers Health (HIMS) is positioned as a disruptive force in traditional healthcare, leveraging digital-first, direct-to-consumer telehealth solutions. Recent legal and regulatory overhangs have eased following a partnership with Novo Nordisk, reducing litigation and enforcement risks. HIMS faces a potentially explosive short squeeze, with 81 million shares sold short and 40-45% of the float at risk.
Novo Nordisk drops Him & Hers lawsuit
Novo Nordisk has dropped its patent lawsuit against Hims & Hers after the telehealth provider agreed to sell Novo's branded medicines. “We've decided to drop the court proceedings and don't expect to revisit them,” CEO Mike Doustdar told CNBC.
Hims stock jumps 50% as Novo Nordisk ends lawsuit, strikes deal
Telehealth platforms are becoming a gateway for access to blockbuster weight loss medicines. That shift became clearer on Monday after Novo Nordisk dropped its patent infringement lawsuit against digital health provider Hims & Hers.
Hims & Hers shares surge 50% after Novo Nordisk ends legal feud over compounded weight loss drugs
"We have decided to drop the current court proceedings," Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back "if needed." It comes after an agreement between Novo and Hims where Hims will offer access to Ozempic and Wegovy at the same price as other telehealth platforms, and no longer advertise compounded GLP-1 drugs.
What's Happening With HIMS Stock?
HIMS has risen 40% pre-market following reports of a settlement and collaboration with Novo Nordisk to market its branded weight-loss drug on the Hims platform.
5 Things to Know Before the Stock Market Opens
Stock futures are sharply lower Monday as investors grow increasingly concerned about the impact of the war in the Middle East on the global economy; Oil prices jumped to their highest level in nearly four years as the war hampers the commodity's supply chain; Hims & Hers Health stock is surging on reports of a deal with Novo Nordisk to sell its weight loss products on the platform; Kalshi and Polymarket are reportedly in talks for new funding rounds that would value the prediction markets at $20 billion each; and HP Enterprise is set to kick off a busy week of earnings. Here's what you need to know today.
Hims shares jump after report of Novo Nordisk partnership that may end legal feud
Hims & Hers' shares were up over 50% in premarket trading on Monday following reports Novo Nordisk plans to sell its weight-loss drugs on the telehealth firm's platform, signaling a potential end to the dispute between the two companies.
